Lutetium [ ¹⁷⁷ Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study.

Autor: Lastoria S; Division of Nuclear Medicine, IRCCS Istituto Nazionale Tumori, 'Fondazione Senatore Giovanni Pascale', Naples, Italy., Rodari M; Nuclear Medicine Unit, IRCCS-Humanitas Clinical and Research Hospital, Rozzano, MI, Italy., Sansovini M; Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), 'Dino Amadori', Meldola, Italy., Baldari S; Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy. sbaldari@unime.it., D'Agostini A; U.O.C. Medicina Nucleare-Ospedale 'S.M. Goretti', Latina, Italy., Cervino AR; Nuclear Medicine Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Filice A; Nuclear Medicine Unit, AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy., Salgarello M; Nuclear Medicine Department, Sacrocuore-Don Calabria Hospital, Negrar di Valpolicella, Italy., Perotti G; Nuclear Medicine Unit, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy., Nieri A; Nuclear Medicine Unit, Onco-Hematological Department, University Hospital of Ferrara, Ferrara, Italy., Campana D; Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Pellerito RE; Nuclear Medicine Unit, Ordine Mauriziano Hospital, Turin, Italy., Pomposelli E; SC Medicina Nucleare, Azienda Ospedaliera-Universitaria SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy., Gaudieri V; Department of Advanced Biomedical Sciences, University ''Federico II'' of Naples, Naples, Italy., Storto G; IRCCS CROB Referral Cancer Center of Basilicata, Rionero in Vulture (Pz), Italy., Grana CM; Radiometabolic Therapy, Nuclear Medicine, IRCCS European Institute of Oncology, Milan, Italy., Signore A; Nuclear Medicine Unit, Department of Medical-Surgical Sciences and Translational Medicine, University Hospital Sant'Andrea, 'Sapienza' University of Rome, Rome, Italy., Boni G; Nuclear Medicine Therapy Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy., Dondi F; Nuclear Medicine, ASST Spedali Civili di Brescia, Brescia, Italy., Simontacchi G; SODc Radiotherapy, Department of Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Seregni E; Nuclear Medicine Unit, IRCCS-Fondazione Istituto Nazionale dei Tumori, Milan, Italy.

Publikováno v: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Sep; Vol. 51 (11), pp. 3417-3427. Date of Electronic Publication: 2024 May 22.

[ ¹⁷⁷ Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.

Autor: Singh S; University of Toronto, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada. Electronic address: simron.singh@sunnybrook.ca., Halperin D; MD Anderson Cancer Center, Houston, TX, USA., Myrehaug S; University of Toronto, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada., Herrmann K; Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; National Center for Tumor Diseases (NCT), NCT West, Heidelberg, Germany., Pavel M; Department of Medicine 1, Uniklinikum Erlangen, and Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Kunz PL; Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA., Chasen B; MD Anderson Cancer Center, Houston, TX, USA., Tafuto S; Sarcoma and Rare Tumors Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, Naples, Italy., Lastoria S; Division of Nuclear Medicine, Istituto Nazionale Tumori IRCCS, Fondazione G Pascale, Naples, Italy., Capdevila J; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., García-Burillo A; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Oh DY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea., Yoo C; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Halfdanarson TR; Mayo Clinic, Rochester, MN, USA., Falk S; Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, UK., Folitar I; Novartis Pharma AG, Basel, Switzerland., Zhang Y; Novartis Pharmaceuticals Corp, East Hanover, NJ, USA., Aimone P; Novartis Pharma AG, Basel, Switzerland., de Herder WW; Erasmus MC and Erasmus MC Cancer Institute, Rotterdam, Netherlands., Ferone D; Endocrinology, IRCCS Policlinico San Martino and DiMI, University of Genova, Genoa, Italy.

Publikováno v: Lancet (London, England) [Lancet] 2024 Jun 29; Vol. 403 (10446), pp. 2807-2817. Date of Electronic Publication: 2024 Jun 05.

MO-06.3 - ACCEPTANCE TESTING AND IMPLEMENTATION IN CLINICAL ROUTINE OF VERITON MULTI-CZT DETECTOR SPECT/CT SYSTEM

Autor: D’Ambrosio, L., Palmese, V. Pirozzi, Prisco, A., Traino, C., Rocca, R., Aurilio, M., Porfidia, V., Buonanno, M., Rossi, A., Carideo, L., Ricci, F., Lastoria, S.

Publikováno v: In Physica Medica November 2023 115 Supplement 1

Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results

Autor: Granata, V., Fusco, R., Piccirillo, M., Palaia, R., Petrillo, A., Lastoria, S., Izzo, F.

Publikováno v: In International Journal of Surgery June 2015 18:230-236

Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group.

Autor: Fazio N; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, Istituto Europeo di Oncologia (IEO) IRCCS, Milan, Italy., Falconi M; Pancreatic Surgery Unit, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy., Foglia E; School of Industrial Engineering and HD LAB-Carlo Cattaneo-LIUC University, Castellanza, Italy., Bartolomei M; Nuclear Medicine Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy., Berruti A; Medical Oncology Unit, ASST Spedali Civili, Brescia, Italy.; Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, Brescia, Italy., D'Onofrio M; Radiology, GB Rossi University Hospital, University of Verona, Verona, Italy., Ferone D; Endocrinology, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova and Endocrinology Clinic, IRCCS, Ospedale Policlinico San Martino, Genoa, Italy., Giordano A; Nuclear Medicine Unit, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.; Section of Nuclear Medicine, Dipartimento Universitario di Scienze Radiologiche ed Ematologia, Università Cattolica del Sacro Cuore, Rome, Italy., Grimaldi F; Endocrinology and Diseases of Metabolism Unit, University Hospital Santa Maria Misericordia, Udine, Italy., Milione M; Anatomia Patologica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Panzuto F; Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University and Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, Rome, Italy., Santimaria M; Nuclear Medicine Unit, S. Bortolo Hospital, AULSS 8 Berica, Vicenza, Italy., Schillaci O; Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy., Seregni E; Nuclear Medicine Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Stasi M; Medical Physics Department, A.O. Ordine Mauriziano di Torino, Turin, Italy., Volante M; Department of Oncology, University of Turin, and Pathology Unit, San Luigi Hospital, Turin, Orbassano, Italy., Lastoria S; Nuclear Medicine and Therapy with Radionuclides, Cyclotron and Radiopharmacy Units, IRCCS National Cancer Institute, Fondazione Senatore G. Pascale, Via M. Semmola, 80131, Naples, Italy. s.lastoria@istitutotumori.na.it.

Publikováno v: Advances in therapy [Adv Ther] 2024 Jan; Vol. 41 (1), pp. 113-129. Date of Electronic Publication: 2023 Nov 21.